The long standing Hematology T32 Training Grant at the University of North Carolina at Chapel Hill (UNC-CH) remains committed to training both MD physician-scientists and PhD scientists for careers in academic hematology and hematology research. This program will continue to train adult and pediatric hematology fellows and PhD post- doctoral candidates in areas of traditional institutional research strengths encompassing benign hematology. Both basic bench and clinical research tracks are available, with carefully selected didactic coursework to complement the training experience. In this competitive renewal application, scientific and educational interactions between MD and PhD trainees in the form of conferences, journal clubs, and symposia have been emphasized. Following 2 years of training on the T32 grant, trainees will be encouraged to apply for individual or institutional K series awards, and/or other sources of independent funding.
For over 35 years, the training program in academic hematology at the University of North Carolina at Chapel Hill (UNC-CH) has benefitted from support by the Ruth L. Kirschstein National Research Service Award. This program, which encompasses disorders of the blood, vasculature or immune system, has been extraordinarily successful in its mission to train clinical and bench researchers in hematology. The cornerstones of training include a mentored research project, focused seminars and conferences, training in the responsible conduct of research, and didactic coursework in clinical research, laboratory methodology, grantsmanship, and the academic community. Both MD and PhD postdoctoral candidates are recruited from intramural and extramural sources, and their frequent interaction during the 2-year period of support engenders a mutual respect and understanding of the ultimate goals of biomedical research in hematologic disorders.
|Vance, Melisa; Llanga, Telmo; Bennett, Will et al. (2016) AAV Gene Therapy for MPS1-associated Corneal Blindness. Sci Rep 6:22131|
|Martin, Karlyn; Key, Nigel S (2016) How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood 128:178-84|
|Martin, Karlyn; Moll, Stephan (2016) Direct oral anticoagulant drug level testing in clinical practice: A single institution experience. Thromb Res 143:40-4|
|Martin, K; Beyer-Westendorf, J; Davidson, B L et al. (2016) Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 14:1308-13|
|Rautou, Pierre-Emmanuel; Tatsumi, Kohei; Antoniak, Silvio et al. (2016) Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury. J Hepatol 64:53-9|
|Martin, K; Kasthuri, R; Mooberry, M J et al. (2016) Lower doses of recombinant porcine factor VIII maintain excellent haemostatic efficacy. Haemophilia 22:e549-e551|
|Geddings, J E; Hisada, Y; Boulaftali, Y et al. (2016) Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost 14:153-66|
|Whelihan, Matthew F; Cooley, Brian; Xu, Yongmei et al. (2016) In vitro and in vivo characterization of a reversible synthetic heparin analog. Thromb Res 138:121-9|
|Sparkenbaugh, Erica M; Chantrathammachart, Pichika; Chandarajoti, Kasemsiri et al. (2016) Thrombin-independent contribution of tissue factor to inflammation and cardiac hypertrophy in a mouse model of sickle cell disease. Blood 127:1371-3|
|Sparkenbaugh, Erica M; Chantrathammachart, Pichika; Wang, Shaobin et al. (2015) Excess of heme induces tissue factor-dependent activation of coagulation in mice. Haematologica 100:308-14|
Showing the most recent 10 out of 51 publications